Exec appointments at SkyePharma, Impax, Ariad and Regeneron

UK-based drug delivery specialist SkyePharma (LSE: SKP) has appointed Pierre Delavaud as executive vice president, sales and business development, at the company’s main R&D facilities in Muttenz, Switzerland. Dr Delavaud has more than 17 years of experience in the pharmaceutical industry, with a strong track record in marketing, sales and global business development of which 14 years have been with the Catalent Group (and its preceding companies). Until recently he was VP sales and business development global pharmaceutical at Softgel.

Impax Laboratories (Nasdaq: IPXL) has named Carole Ben-Maimon, as president of its Global Generic Pharmaceutical division. Dr Ben-Maimon, who was most recently senior vice president, corporate strategy consulting to the president, chief executive and investors at Qualitest Pharmaceuticals, will report to Impax’ president and CEO and be responsible for expanding the group’s generic business in the USA.

Also Ariad Pharmaceuticals (Nasdaq: ARIA) has appointed Martin Duvall as senior vice president, commercial operations, reporting to CEO Harvey Berger. In this role, Mr Duvall will be responsible for global commercialization of Ariad’s investigational pan-BCR-ABL inhibitor, ponatinib for intolerant chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. He joins Ariad from Merck & Co, where he served as senior vice president and general manager of Merck's global oncology franchise since 2010.